



Contact Information:

Dennis Dionne
Saladax Biomedical
610.419.6731 ext 26517
DDionne@Saladax.com

Saladax Biomedical Launches First Analyte Specific Reagent* (ASR) for Determination of Busulfan Blood Concentrations.

Doylestown, PA, May 18, 2007 — Saladax Biomedical, Inc. (SBI) launched its first two ASR products – Busulfan Antibody ASR and Busulfan Conjugate ASR – that will enable clinical laboratories to develop tests in-house for timely and cost-effective determination of serum concentrations of the chemotherapeutic agent, busulfan (Busulfex®, Myleran®).

Annually, over 60,000 hematopoietic stem cell transplants are performed worldwide, with approximately 30 percent performed in the United States. Busulfan is commonly used in the preparative regimen prior to transplant. The drug can be quite toxic, particularly in pediatric patients, for whom dose management by blood level monitoring is recommended. However, the technologies utilized to perform the blood analysis to establish concentrations are laborious, expensive and time-consuming. Often, laboratories can not turn around a test result in sufficient time to adjust the dose into the optimal range during therapy. These SBI ASRs enable qualified laboratories to generate over eighty test results per hour with a small blood sample and no sample pre-treatment using an ELISA format.

“The introduction of the first ASR’s is a significant milestone for Saladax,” said Salvatore J. Salamone, SBI Chairman and Chief Executive Officer. “The Busulfan Antibody ASR constitutes the first antibody ever generated to this drug, recognized by a recently issued patent from the US Patent Office. Our antibodies are specific to the active form of busulfan and do not cross-react with any known metabolites. As a result, laboratories can offer the highest quality testing more efficiently to meet clinical needs.”

SBI’s ASRs are manufactured under good manufacturing practices (cGMPs) in compliance with 21 CFR 864.4020 and 21 CFR820. SBI is registered with the US FDA to develop, manufacture and sell ASRs.

* Analyte Specific Reagent (ASR) – Analytical and performance characteristics are not established. ASRs can be sold in the US only to clinical laboratories regulated under the CLIA of 1988, as qualified to perform highly complexity testing under 42 CFR Part 493 or under VHA directive 1106.

About Saladax

Saladax Biomedical is pioneering the development of novel, rapid, and cost-effective immunoassays that will enable routine blood-level monitoring of anti-cancer drugs to become the standard of care in treating cancer patients. With Personalized Chemotherapy Management (PCM), oncologists will be able to adjust the administered dose based on each patient's individual drug level, leading to reduced toxicity, improved outcome and lower cancer care costs. Saladax is headquartered at the business incubator of the Ben Franklin Technology Partners (BFTP) of Northeastern Pennsylvania on the campus of Lehigh University in Bethlehem. The 5-FU PCM test will be available to U.S. clinicians later this year through a major reference laboratory.